Lynx1 Capital Management LP 13D and 13G filings for Stoke Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 09:00 am Purchase |
2024-09-30 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 5,187,191 9.900% |
2,230,273 (+75.43%) |
Filing |
| 2024-02-14 09:20 am Purchase |
2023-12-31 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 2,956,918 6.600% |
292,760 (+10.99%) |
Filing |
| 2023-11-06 4:55 pm Purchase |
2023-10-26 | 13G | Stoke Therapeutics, Inc. STOK |
Lynx1 Capital Management LP | 2,664,158 6.000% |
2,664,158 (New Position) |
Filing |